HN1997000167A - Combinaciones para diabetes de sulfonilurea glitazona - Google Patents

Combinaciones para diabetes de sulfonilurea glitazona

Info

Publication number
HN1997000167A
HN1997000167A HN1997000167A HN1997000167A HN1997000167A HN 1997000167 A HN1997000167 A HN 1997000167A HN 1997000167 A HN1997000167 A HN 1997000167A HN 1997000167 A HN1997000167 A HN 1997000167A HN 1997000167 A HN1997000167 A HN 1997000167A
Authority
HN
Honduras
Prior art keywords
combinations
glitazone
sulfonilurea
diabetes
antidiabetic agent
Prior art date
Application number
HN1997000167A
Other languages
English (en)
Spanish (es)
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HN1997000167A publication Critical patent/HN1997000167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HN1997000167A 1997-02-19 1997-12-30 Combinaciones para diabetes de sulfonilurea glitazona HN1997000167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19

Publications (1)

Publication Number Publication Date
HN1997000167A true HN1997000167A (es) 1999-02-09

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1997000167A HN1997000167A (es) 1997-02-19 1997-12-30 Combinaciones para diabetes de sulfonilurea glitazona

Country Status (29)

Country Link
US (2) US5859037A (enExample)
EP (1) EP0957923A1 (enExample)
JP (1) JP2001512478A (enExample)
KR (1) KR20000071179A (enExample)
CN (1) CN1244801A (enExample)
AR (1) AR011829A1 (enExample)
AU (1) AU741215B2 (enExample)
BG (1) BG103671A (enExample)
BR (1) BR9714505A (enExample)
CA (1) CA2272478A1 (enExample)
CZ (1) CZ289299A3 (enExample)
EA (1) EA199900725A1 (enExample)
EE (1) EE9900345A (enExample)
GT (1) GT199800037A (enExample)
HN (1) HN1997000167A (enExample)
HU (1) HUP0001528A3 (enExample)
IL (1) IL130027A (enExample)
IS (1) IS5058A (enExample)
NO (1) NO993982D0 (enExample)
NZ (1) NZ336002A (enExample)
PA (1) PA8447401A1 (enExample)
PE (1) PE74399A1 (enExample)
PL (1) PL335166A1 (enExample)
SK (1) SK111899A3 (enExample)
SV (1) SV1998000010A (enExample)
TR (1) TR199902033T2 (enExample)
UY (1) UY24893A1 (enExample)
WO (1) WO1998036755A1 (enExample)
ZA (1) ZA981343B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
ATE353654T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und sulphonylurea
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
WO1998057634A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
ATE300288T1 (de) * 1998-12-24 2005-08-15 Metabasis Therapeutics Inc Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
AU784108B2 (en) * 1999-03-15 2006-02-02 University Of British Columbia, The Methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
TR200401145T4 (tr) 2000-04-13 2004-07-21 Pfizer Products Inc. Gliburit ve milrinonun sinerjistik etkisi.
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP1539144B1 (en) 2002-09-20 2014-12-24 Andrx Labs Llc Multistage formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
AU2004285354B2 (en) 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
US20090227493A1 (en) * 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
AU2006289259A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
RU2426530C2 (ru) 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
WO2009073711A1 (en) 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
KR20200022525A (ko) * 2008-12-04 2020-03-03 충시 위 고투과력을 가진 조성물 및 이의 적용
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
WO2011059053A1 (ja) * 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
BR112012029858B1 (pt) 2010-05-24 2021-01-19 Ozstar Therapeutics Pty Ltd. uso de inulina para fabricação de um medicamento
EP4282363A3 (en) 2011-01-19 2024-01-10 Fractyl Health, Inc. Devices for the treatment of tissue
KR102104384B1 (ko) * 2011-11-23 2020-04-27 오즈스타 테라피우틱스 피티와이 엘티디 개선된 상승작용성 항-당뇨병성 조성물
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
JP6167115B2 (ja) 2012-02-27 2017-07-19 フラクティル ラボラトリーズ インコーポレイテッド 組織の治療のための熱切除システム、デバイスおよび方法
KR102231179B1 (ko) 2012-04-19 2021-03-22 프랙틸 래브러토리스 인코포레이티드 조직 팽창 디바이스들, 시스템들, 및 방법들
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
EP3043732B1 (en) 2013-09-12 2021-04-07 Fractyl Laboratories, Inc. Systems and devices for treatment of target tissue
KR102284469B1 (ko) 2013-11-22 2021-08-02 프랙틸 헬쓰, 인코포레이티드 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
EP4090282A4 (en) 2020-01-15 2024-02-21 Fractyl Health, Inc. AUTOMATED TISSUE TREATMENT DEVICES, SYSTEMS AND METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AU741215B2 (en) 2001-11-29
AR011829A1 (es) 2000-09-13
NO993982L (no) 1999-08-18
SV1998000010A (es) 1999-02-02
EP0957923A1 (en) 1999-11-24
SK111899A3 (en) 2000-09-12
BR9714505A (pt) 2000-03-21
ZA981343B (en) 1998-11-16
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
IL130027A (en) 2005-09-25
US5859037A (en) 1999-01-12
EE9900345A (et) 2000-02-15
PL335166A1 (en) 2000-04-10
AU5590898A (en) 1998-09-09
NZ336002A (en) 2002-03-28
TR199902033T2 (xx) 2000-02-21
BG103671A (en) 2000-04-28
CZ289299A3 (cs) 1999-11-17
PE74399A1 (es) 1999-08-20
JP2001512478A (ja) 2001-08-21
CN1244801A (zh) 2000-02-16
PA8447401A1 (es) 2001-12-14
WO1998036755A1 (en) 1998-08-27
CA2272478A1 (en) 1998-08-27
NO993982D0 (no) 1999-08-18
HUP0001528A3 (en) 2000-12-28
KR20000071179A (ko) 2000-11-25
UY24893A1 (es) 1998-07-10
EA199900725A1 (ru) 2000-04-24
IS5058A (is) 1999-05-27
US5972973A (en) 1999-10-26
IL130027A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
HN1997000167A (es) Combinaciones para diabetes de sulfonilurea glitazona
PA8484901A1 (es) Combinaciones para la diabetes
FI971420A7 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
ES2142380T3 (es) Hormona paratiroide y raloxifeno para el aumento de la masa osea.
ES2174949T3 (es) Equipo para la amoladura de muestras de material.
ATE314393T1 (de) Verzögerte freigabe von insulinotropin (glp-1)
AR241008A1 (es) Procedimiento para el montaje de un ascensor y el ascensor obtenido por el mismo''
ES2137888B1 (es) Agente antifungico, compuesto para el mismo procedimiento para su produccion y metodo para su utilizacion.
DE69405491D1 (de) Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
DE69015024D1 (de) Unter Feldeffekt-Emission arbeitende Schaltanordnung und deren Herstellungsverfahren.
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
BR9707588A (pt) Agente terapeutico para diabetes
MX171741B (es) Composicion de agente alargador de cadena a base de 4,4'-metilenbisanilinas cloradas para prepolimeros de p-fenilen-metilendiisocianato, para elastomeros de poliuretano vaciados
ECSP982417A (es) Combinaciones para diabetes de sulfonilurea glitazona
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
ECSP993207A (es) Combinaciones para la diabetes
BR9811344B1 (pt) mÉtodo para aumentar a expressço de proteÍna exàgena.
EA200000040A1 (ru) Способ лечения диабета тиазолидиндионом и ингибитором альфа-глюкозидазы
MX9205459A (es) Compuesto de organosilicio para el tratamiento de fibras de poliester, metodo para el tratamiento de las fibras de poliester y las fibras asi producidas.
FI895431A0 (fi) Material, foerdelaktigt i bandform foer anvaendning som omslagsmaterial.
AR001321A1 (es) Toxinas noveles.
DK0968715T3 (da) Loratadin til anvendelse som et antiarytmikum
DE69022627D1 (de) Betätigungsvorrichtung für Notsteuerung.
DE59009399D1 (de) Stelleinrichtung für Regelglieder.
SE8400569L (sv) Produkt som utgor substitut for kroppsvevnad